A61K 40/4276
Prostate specific membrane antigen [psma]
Official title: {Prostate specific membrane antigen [PSMA]}
A61K40/4276 (Prostate specific membrane antigen [psma]) appears on 68 US grants and 168 published applications in this corpus.
Search patents in A61K- Granted patents
- 68
- Published applications
- 168
- Assignees
- 82
- Inventors
- 323
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 3 |
| 2009 | 0 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 4 |
| 2012 | 1 | 0 |
| 2013 | 2 | 3 |
| 2014 | 0 | 1 |
| 2015 | 1 | 4 |
| 2016 | 1 | 6 |
| 2017 | 2 | 6 |
| 2018 | 6 | 10 |
| 2019 | 1 | 9 |
| 2020 | 8 | 15 |
| 2021 | 3 | 16 |
| 2022 | 7 | 17 |
| 2023 | 7 | 18 |
| 2024 | 9 | 22 |
| 2025 | 11 | 16 |
| 2026 | 8 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Fusion constructs and methods of using thereof11 Aug 2026US 12,703,747 B2Precigen, Inc.
- Chimeric antigen receptors targeting CD127 and use thereof4 Aug 2026US 12,697,388 B2Memorial Sloan Kettering Cancer Center
- Selective stimulation of T cells in solid tumors using oncolytic viral delivery of orthogonal IL-223 Jun 2026US 12,661,401 B2The Regents of the University of California
- PSMA-targeted immunotherapies for cancers21 Apr 2026US 12,605,446 B2The Methodist Hospital
- Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors3 Sep 2026US 2026/0258355 A1The Trustees of the University of Pennsylvania
- Prostate-specific membrane antigen targeted nf-kb p50-deficient immature myeloid cells27 Aug 2026US 2026/0248849 A1The Johns Hopkins University
- Synthetic antigen receptors for covalent immune recruiters and methods and uses thereof27 Aug 2026US 2026/0248852 A1McMaster University
- Bi-specific adapters and their use with universal car-t cells in the treatment of tumors and the inhibition of cancer-associated fibroblasts27 Aug 2026US 2026/0248923 A1Purdue Research Foundation
- In vivo and ex vivo production of car-neutrophils and use thereof to treat and image cancer23 Jul 2026US 2026/0207776 A1Purdue Research Foundation
Most cited
By later US patents
- Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes244US 8,389,282 B2Memorial Sloan Kettering Cancer Center · 2013
- Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy72US 5,788,963 APacific Northwest Cancer Foundation · 1998
- Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes43US 9,220,728 B2Memorial Sloan Kettering Cancer Center · 2015
- Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods23US 8,486,693 B2Bellicum Pharmaceuticals, Inc. · 2013
- Methods for inducing partial apoptosis using caspase polypeptides16US 9,913,882 B2Bellicum Pharmaceuticals, Inc. · 2018